Inactive Instrument

Arch Therapeutics Inc Stock OTC Bulletin Board

Equities

Medical Equipment, Supplies & Distribution

Sales 2022 0.02 Sales 2023 0.08 Capitalization 6.1M
Net income 2022 -5M Net income 2023 -6M EV / Sales 2022 473,469,716 x
Net Debt 2022 2.62M Net Debt 2023 5.41M EV / Sales 2023 151,885,320 x
P/E ratio 2022
-0.87 x
P/E ratio 2023
-0.57 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 74.87%
More Fundamentals * Assessed data
Dynamic Chart
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Arch Therapeutics, Inc. to Present AC5®? Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) CI
Arch Therapeutics, Inc. Provides Commercialization Update on the First Product, AC5 Advanced Wound System CI
Arch Therapeutics, Inc. announced that it has received $2.560063 million in funding CI
Arch Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Arch Therapeutics, Inc. announced that it expects to receive $1.850001 million in funding CI
Arch Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Arch Therapeutics to Present AC5(R) Advanced Wound System At 2023 Symposium on Advanced Wound Care CI
Arch Therapeutics, Inc. Announces Dedicated HCPCS Billing Code for its Advanced Wound System Now in Effect CI
Arch Therapeutics' AC5(R) Advanced Wound System Receives Dedicated HCPCS Billing Code from the Centers for Medicare & Medicaid Services CI
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of Ac5® Advanced Wound System in Government Facilities CI
Arch Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System CI
Arch Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 09-09-15
Director of Finance/CFO 55 21-05-09
Sales & Marketing - 20-12-31
Members of the board TitleAgeSince
Chief Executive Officer 59 09-09-15
Director/Board Member 64 21-12-30
Director/Board Member - 21-09-26
More insiders
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.
More about the company